Oppenheimer reiterated their buy rating on shares of Colfax (NYSE:CFX) in a research report sent to investors on Monday morning.

Other equities research analysts also recently issued research reports about the company. Zacks Investment Research upgraded Colfax from a hold rating to a buy rating and set a $38.00 target price on the stock in a research report on Thursday, August 9th. Robert W. Baird restated a buy rating and issued a $38.00 target price (up previously from $36.00) on shares of Colfax in a research report on Monday, August 6th. Barclays lifted their target price on Colfax from $29.00 to $30.00 and gave the company an underweight rating in a research report on Wednesday, August 8th. ValuEngine downgraded Colfax from a sell rating to a strong sell rating in a research report on Friday, October 19th. Finally, CIBC upgraded Colfax from a market perform rating to an outperform rating in a research report on Tuesday, September 4th. Four equities research analysts have rated the stock with a sell rating, five have issued a hold rating and eleven have assigned a buy rating to the company’s stock. Colfax has an average rating of Hold and a consensus target price of $34.77.

NYSE:CFX opened at $23.72 on Monday. Colfax has a 52 week low of $23.15 and a 52 week high of $42.08. The company has a current ratio of 1.83, a quick ratio of 1.37 and a debt-to-equity ratio of 0.33. The firm has a market capitalization of $3.28 billion, a price-to-earnings ratio of 13.63, a price-to-earnings-growth ratio of 0.92 and a beta of 1.56.

Colfax (NYSE:CFX) last posted its earnings results on Thursday, October 25th. The industrial products company reported $0.54 EPS for the quarter, beating the Zacks’ consensus estimate of $0.52 by $0.02. Colfax had a return on equity of 6.97% and a net margin of 3.03%. The company had revenue of $875.37 million for the quarter, compared to the consensus estimate of $893.38 million. On average, research analysts predict that Colfax will post 2.25 EPS for the current fiscal year.

In other news, SVP Jason Maclean sold 1,120 shares of Colfax stock in a transaction on Thursday, November 8th. The stock was sold at an average price of $29.06, for a total value of $32,547.20. Following the completion of the sale, the senior vice president now directly owns 9,716 shares of the company’s stock, valued at $282,346.96. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Insiders own 10.20% of the company’s stock.

Several hedge funds and other institutional investors have recently modified their holdings of the company. Putnam Investments LLC acquired a new stake in shares of Colfax in the third quarter valued at $6,340,000. Point72 Asset Management L.P. acquired a new stake in shares of Colfax in the third quarter valued at $11,891,000. TLP Group LLC grew its stake in shares of Colfax by 166,250.0% in the third quarter. TLP Group LLC now owns 3,327 shares of the industrial products company’s stock valued at $120,000 after buying an additional 3,325 shares in the last quarter. Man Group plc acquired a new stake in shares of Colfax in the third quarter valued at $1,291,000. Finally, Paloma Partners Management Co acquired a new stake in shares of Colfax in the third quarter valued at $772,000. 78.57% of the stock is owned by institutional investors and hedge funds.

About Colfax

Colfax Corporation operates as a diversified industrial technology company worldwide. The company operates through Air and Gas Handling, and Fabrication Technology segments. The Air and Gas Handling segment designs, manufactures, and supplies heavy-duty centrifugal and axial fans, rotary heat exchangers, and gas compressors, as well as related products, systems, and services.

See Also: Average Daily Trade Volume – What It Means In Stock Trading

Analyst Recommendations for Colfax (NYSE:CFX)

Receive News & Ratings for Colfax Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Colfax and related companies with MarketBeat.com's FREE daily email newsletter.